Fig. 3: Tregs are hypersensitive to BAY1082439. | Nature Communications

Fig. 3: Tregs are hypersensitive to BAY1082439.

From: Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Fig. 3

A The differential inhibitory effects of BAY1082439 on T cells. Primary CD8+, helper T and Treg cells from spleen of WT mice were FACS sorted, and cultured with different concentrations of BAY1082439. This experiment was repeated 3 times the percentages of cell growth as compared to vehicle controls were presented. Data were presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 by two-sided T-test. IC50s were calculated by GraphPad Prism 6 software. B, C. Prostate- and spleen-associated Treg cell numbers and the percentages of Treg in CD4+ T cell in vehicle (n = 17), BAY-D (n = 7) and BAY-I (n = 13) treated cohorts were analyzed by FACS. Data were presented as dot plots with mean as the central lines; **p < 0.01, ***p < 0.001 by two-sided T-test. D The negative correlation between the percentages of CD8+ in CD45+ and Treg in CD4+ cells by Pearson correlation coefficient. E The CD8+/Treg ratios in vehicle, BAY-D and BAY-I treated cohorts analyzed by FACS. Data were presented as dot plots with mean as the central lines; *p < 0.05 by two-sided T-test. Source data and exact p values are provided in the Source Data file.

Back to article page